Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD treatment the company is developing with GlaxoSmithKline (GSK +3.1%) — could be set for approval by the FDA which will evaluate a recommendation Wednesday. There were some questions about side effects which Citi and UBS analysts said were expected. THRX will get royalties of 15% on the first $3B in sales and 5% thereafter.
Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD...
From other sites
at CNBC.com (Jun 11, 2014)
at CNBC.com (Dec 6, 2013)
at CNBC.com (Sep 10, 2013)
at CNBC.com (Jun 24, 2013)
at CNBC.com (Apr 15, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs